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The Journal of Immunology
T Cell Immunity to the Alkyl Hydroperoxide Reductase of
Burkholderia pseudomallei: A Correlate of Disease Outcome
in Acute Melioidosis
Catherine Reynolds,* Ame´lie Goudet,† Kemajittra Jenjaroen,‡ Manutsanun Sumonwiriya,‡
Darawan Rinchai,x Julie Musson,{ Saskia Overbeek,* Julia Makinde,* Kathryn Quigley,*
Jiten Manji,* Natasha Spink,‖ Pagnarith Yos,# Vanaporn Wuthiekanun,‡ Gregory Bancroft,‖
John Robinson,{ Ganjana Lertmemongkolchai,x Susanna Dunachie,‡,** Bernard Maillere,†
Matthew Holden,†† Daniel Altmann,* and Rosemary Boyton*
There is an urgent need for a better understanding of adaptive immunity toBurkholderia pseudomallei, the causative agent of melioidosis
that is frequently associated with sepsis or death in patients in Southeast Asia and Northern Australia. The imperative to identify vaccine
targets is driven both by the public health agenda in these regions and biological threat concerns. In several intracellular bacterial
pathogens, alkyl hydroperoxidase reductases are upregulated as part of the response to host oxidative stress, and they can stimulate
strong adaptive immunity. We show that alkyl hydroperoxidase reductase (AhpC) of B. pseudomallei is strongly immunogenic for T cells
of ‘humanized’ HLA transgenic mice and seropositive human donors. Some T cell epitopes, such as p6, are able to bind diverse HLA
class II heterodimers and stimulate strong T cell immunity in mice and humans. Importantly, patients with acute melioidosis who
survive infection show stronger T cell responses to AhpC relative to those who do not. Although the sequence of AhpC is virtually
invariant among global B. pseudomallei clinical isolates, a Cambodian isolate varies only in C-terminal truncation of the p6 T cell
epitope, raising the possibility of selection by host immunity. This variant peptide is virtually unable to stimulate T cell immunity. For an
infection in which there has been debate about centrality of T cell immunity in defense, these observations support a role for T cell
immunity to AhpC in disease protection. The Journal of Immunology, 2015, 194: 4814–4824.
M
elioidosis is increasingly considered a major and
emerging public health risk in several countries in
Southeast Asia, including Thailand, Cambodia, and
Laos, as well as the northern territories of Australia (1–3). The
disease, caused by environmental exposure to the gram-negative
bacterium Burkholderia pseudomallei, is associated with hetero-
geneous presentations, from asymptomatic seroconversion to lo-
calized tissue infections, lung and brain abscesses, pneumonia,
sepsis, and death. Diabetes is a major risk factor for severe,
symptomatic disease (4). There are concerns that the disease is
underreported in regions of similar latitude in Asia, African, and
South America and that this, coupled with the growing prevalence
of diabetes in these areas, may lead to a considerable increase in
the melioidosis disease burden, with an at-risk population of .1
billion people (5). Furthermore, there is considerable sequence
conservation between this bacterium and the related Burkholderia
species, Burkholderia cepacia complex, that threaten the
health of cystic fibrosis patients, making the question of T cell
immunity to Burkholderia Ags one of relevance also in this
context (6, 7).
The immunologic correlates of protection and susceptibility
in this infection are poorly understood. Studies in murine models
suggest that T cell–mediated IFN-g responsiveness is important
for protection (8). In humans, the immune correlates of disease
susceptibility are somewhat unclear (9). The fact that diabetes is
a risk factor associated with poor survival suggests a predisposing
role of immune dysregulation, although the precise mechanisms
have not been established (10).
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Nearly 200 B. pseudomallei genomes of isolates derived from
several countries have been sequenced. Genome size is variable,
with an average size of 7.15 Mb. Faced with the challenge of
establishing immunogenicity and immunodominance in a genome
of this size, Felgner et al. (11) reported a protein array approach
to serologic screening. A B. pseudomallei proteome array was
expressed on chips carrying 1205 proteins predicted to be surface-
expressed by PSORT, as well as components of the three different
type III systems, components of flagella, proteins known to be
immunoreactive from two-dimensional gels and 672 other pro-
teins selected at random. These 1205 proteins were screened
against 747 individual patient sera from 10 patient groups, in-
cluding melioidosis patients and healthy seropositive donors from
Thailand and Singapore; 108 Ags were described as immunodo-
minant, and 31 were serodiagnostic for melioidosis. Burkholderia
pseudomallei is an intracellular pathogen, making it highly likely
that an effective vaccine may need to be able to activate both
T cell and B cell immunity. Both a translational interest in vaccine
targets and a basic interest in how the host recognizes what is
essentially an intracellular pathogen of APCs highlights a need to
understand T cell immunity in melioidosis.
One of the serodominant B. pseudomallei Ags identified in the
protein array study was the alkyl hydroperoxide reductase (AhpC)
BPSL2096. It is a member of the highly conserved family of
peroxiredoxins, first described in yeast in the mid-1990s, with
respect to the ability to protect against oxidation by reducing
hydroperoxides in a thiol environment (12). In eukaryotic cells,
family members are implicated in regulating resting levels of
cellular peroxide to calibrate the difference between damaging
oxidative stress and a beneficial role in signal transduction (13).
For example, peroxiredoxin-2 is one of the most abundant RBC
proteins after hemoglobin (14). The hydroperoxide reductases are
represented in most bacterial species, where production of anti-
oxidant enzymes is considered a key defense against oxidative
DNA damage (15). Biofilm-derived Burkholderia cenocepacia are
resistant to high concentrations of reactive oxygen species, at-
tributable to transcriptional upregulation of AhpC (.40-fold) and
other genes involved in the response to reactive oxygen species
(16).
A key issue is the effect of human genetic heterogeneity, es-
pecially of HLA alleles, on the immune repertoire and the disease
outcomes (17). In this study, we investigated whether there are
shared patterns of immune response that transcend these genetic
differences. The hope is that answers to these questions will fa-
cilitate novel vaccine strategies.
Materials and Methods
Ethics statement
Mouse experiments were performed within U.K. Home Office legislation
under the terms of the Project License PPL 70/7708 and 70/8110 granted for
this work under the “Animals (Scientific Procedures) Act 1986.” Local
ethical review and formal approval had also been obtained through the
Imperial College Ethical Review Process Committee. Leukocytes from
exposed seropositive donors to the blood bank in Khon Kaen, Thailand,
were collected through the Blood Transfusion Center, Khon Kaen Hospital
(Khon Kaen, Thailand). Ethical permission was obtained from Ethical
Khon Kaen University research no. HE470506. Blood was collected from
41 patients with cultured-confirmed melioidosis at Sappasitthiprasong
Hospital, Ubon Ratchathani, at a median of 5 d after admission to hospital
(interquartile range 4–6 d). Ethical approval was obtained from the Ethics
Committee of the University of Mahidol Faculty of Tropical Medicine
(submission number TMEC 12-014), the Ethics Committee of Sappa-
sitthiprasong Hospital, Ubon Ratchathani (reference 018/2555), and the
Oxford Tropical Research Ethics Committee (reference 64-11). The study
was conducted according to the principles of the Declaration of Helsinki
(2008) and the International Conference on Harmonization Good Clinical
Practice guidelines. Written informed consent was obtained for all patients
enrolled in the study.
BPSL 2096 protein and peptides
The AhpC (BPSL2096) sequence (accession no. YP_108693.1) of
B. pseudomallei was cloned, recombinant AhpC expressed in Escherichia
coli, and purified (Biomatik, Cambridge, ON, Canada). Synthetic peptides
of 20 aa in length and overlapping by 10 aa based on the sequence
of B. pseudomallei strain K96243 were synthesized by GL Biochem
(Shanghai, China) (Table I).
HLA-peptide binding assays
HLA-DR and -DQ heterodimers were purified from B cell lines by affinity
purification on L243 (HLA-DR) or SPVL3 (HLA-DQ). Peptide binding was
evaluated with competitive ELISA using an automated workstation (7, 18–
21). HLA heterodimers were incubated with biotinylated indicator peptide
and serial dilutions of competitor peptide. As reference peptides, unlabeled
forms of the biotinylated indicator peptide were used to assess validity in
each experiment. The following reference sequences were used as labeled
indicator peptides, and their IC50 values are indicated in parentheses: HA
306-318 (PKYVKQNTLKLAT) for DRB1*01:01 (2 nM), DRB1*04:01
(14 nM) and DRB1*11:01 (72 nM) and DRB5*01:02 (18 nM), YKL
(AAYAAAKAAALAA) for DRB1*07:01 (5 nM); A3 152–166 (EAEQL-
RAYLDGTGVE) for DRB1*15:01 (41 nM), MT 2–16 (AKTIAYDEEARRGLE)
for DRB1*03:01 (71 nM), B1 21–36 (TERVRLVTRHIYNREE) for DRB1*13:01
(46 nM), CTP 427–441 (VHGFYNPAVSRIVEA) for DRB1*09:01 (23 nM),
TFR141–155 (TGTIKLLNENSYVPR) (360 nM) for DRB1*12:02, TFR607–620
(LNLDYERYNSQLLS) for DRB1*15:02 (4 nM). B7150–164 (LNEDLRSW-
TAADTAA) for DQ6 (DQA1*01:03/DQB1*06:03) (37 nM) and DQB45–57
(ADVEVYRAVTPLGPPD) for DQ8 (DQA1*03:01/DQB1*03:02; 98 nM).
After 24–72 h incubation (37˚C), samples were neutralized with 50 ml
450 mM Tris HCl (pH 7.5), 0.3% BSA, 1 mM DM buffer and applied to
96-well MaxiSorp ELISA plates (Nunc) coated with 10 mg/ml L243.
Bound biotinylated peptide was detected by streptavidin-alkaline phos-
phatase conjugate (GE Healthcare, Saclay, France). Emitted fluorescence
was measured at 450 nm upon excitation at 365 nm. The peptide con-
centration preventing 50% binding of labeled peptide (IC50) was evaluated
and data expressed as relative affinity: the ratio of the IC50 of test peptide
to the IC50 of reference peptide. Mean 6 SEM was calculated from two to
three independent experiments. Relative affinities of 10 or less were
considered high binders, and relative affinities of 10–100 were moderate
binders (Tables II, III, Supplemental Table I).
HLA transgenic mouse studies
This study used HLA class II transgenic mouse lines for the alleles HLA-
DR1 (DRB1*0101), HLA-DR4 (DRB1*0401), HLA-DQ6 (DQB1*0602),
and HLA-DQ8 (DQB1*0302), which were in each case maintained in the
context of a homozygous knockout for murine H2-Ab, as described pre-
viously (7, 18–20). Mice were maintained in individually ventilated cages
and were used in experiments as age- and sex-matched, young adults. For
CD4 T cell epitope mapping studies, mice were primed in one hind footpad
with 25 mg Ag emulsified in Hunters Titermax Gold adjuvant (Sigma-
Aldrich). At day 10, the draining popliteal lymph node was removed
and disaggregated into a single-cell suspension for ELISPOT assays. The
frequency of cells producing IFN-g in response to Ag was quantified with
ELISPOT (Diaclone; 2B Scientific, Oxon, U.K.) performed in HL-1
serum-free medium (BioWhittaker; Lonza, Slough, U.K.), supplemented
with L-glutamine and penicillin–streptomycin (Life Technologies, Paisely,
U.K.). Cells (2 3 105) plus Ag were added to wells and plates and were
incubated for 72 h at 37˚C with 5% CO2. Unless otherwise indicated,
peptide was added to wells at a final concentration of 25 mg/ml. Spots were
counted on an automated ELISPOT reader (Autoimmun Diagnostika,
Strasbourg, France). Response frequencies were expressed as DSFC/106
cells, with the presence of an epitope being confirmed when the majority of
mice in the immunized group responded with a magnitude greater than the
mean number of spot-forming cells (SFCs) in medium only control + 2 SD.
Mean + 2 SD background SFC for murine ELISPOT data are indicated in
each case by a dotted line on the figures. The ELISPOT background ranges
(per 106 cells) were 0 to 30 SFC.
Human cohorts and T cell assays
Leukocytes from healthy blood donors were collected (Blood Transfusion
Center, Khon Kaen Hospital, Khon Kaen, Thailand). B. pseudomallei se-
ropositive samples were selected on the basis of indirect hemagglutina-
tion assay titers $ 1:40 (22). HLA-DRB1 and DQB1 genotypes were
determined with PCR sequence-specific primer (PCR-SSP) as previously
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described (23). PBMCs were isolated by Ficoll-Hypaque (Sigma-Aldrich)
density gradient centrifugation and stored at 280˚C until use. The fre-
quency of T cell response to AhpC peptides was evaluated by IFNg
ELIspot (C.T.L.). Precoated 96-well polyvinylidene difluoride plates
(MSIP; Millipore) were incubated overnight with 15 mg/ml IFN-g Ab. One
hundred microliter of cells at 2.53 106 cells/ml, pulsed with 100 ml of 53
107 CFU/ml of killed B. pseudomallei as positive control, with 50 mg/ml
individual AhpC individual peptides or with medium alone as a negative
control, were added in triplicate. Plates were cultured for 48 h, and IFN-g
secretion was detected by adding human IFN-g detection solution for 2 h.
IFN-g–producing cells were quantified with Immunospot analyzer (C.T.L.).
Results are expressed as mean SFC per 106 cells of triplicates in the
presence of Ag minus mean spots in the medium control (DSFC), and they
are considered significant if values are above the mean medium-only
control + 2 SD. The background range for these human ELISPOT data
are shown in Fig. 2A (media only).
Blood was collected from 41 patients with culture-confirmed melioidosis
at Sappasitthiprasong Hospital, Ubon Ratchathani, at a median of 5 d after
admission to hospital (interquartile range 4–6 d). PBMCs were separated
from heparinized blood by density centrifugation and counted with a
Scepter handheld counter (Millipore) and cryopreserved at 280˚C before
transfer on dry ice to liquid nitrogen storage at Mahidol Oxford Tropical
Medicine Research Unit. Cellular responses to 20 mg/ml AhpC protein,
1 mg/ml T cell epitope pool (Mabtech AB) and 2 mg/ml of a scrub typhus
Ag r47 were measured with an 18-h IFN-g ELISPOT assay using 96-well
Multiscreen-I plates (Millipore) and a proprietary kit (Mabtech AB)
according to the manufacturer’s instructions. To evaluate HLA class I and
class II restriction of T cell responses to AhpC protein, additional ELI-
SPOT assays were performed in the presence and absence of the anti-class
I Ab (W6/32) and anti-class II Abs L243 (DR) and SPVL3 (DQ), used at
a final concentration of 25 mg/ml. Plates were read using a CTL ELISPOT
reader, and results were expressed as IFN-g SFCs per 1 million PBMCs
with subtraction of background responses in unstimulated control wells.
Responses were defined as positive if values were greater than the mean of
the medium only control + 2 SD and a minimum of 20 SFCs per 1 million
PBMCs. Donor samples showing a highly nonspecific background re-
sponse in the absence of Ag were not used. The median background
ELISPOT measurement in SFCs (per 106 cells) was 10 (range, 0–180), and
there was no significant difference in background measurements between
groups (by Mann–Whitney U test).
Table I. AhpC BPSL2096 peptide panel (accession no. YP_108693.1)
Peptide Peptide Name AA Sequence
1 BPSL2096 (1–20) MKTVGDKLEAFTVVAAKPGF
2 BPSL2096 (11–30) FTVVAAKPGFNNHEENGQSA
3 BPSL2096 (21–40) NNHEENGQSAFETVTEASFP
4 BPSL2096 (31–50) FETVTEASFPGKWKIIYFYP
5 BPSL2096 (41–60) GKWKIIYFYPKDFTFVCPTE
6 BPSL2096 (51–70) KDFTFVCPTEIVEFAKLAKQ
7 BPSL2096 (61–80) IVEFAKLAKQFEERDAVLLG
8 BPSL2096 (71–90) FEERDAVLLGGSSDNEFVKL
9 BPSL2096 (81–100) GSSDNEFVKLAWRREHKDLD
10 BPSL2096 (91–110) AWRREHKDLDKLNHYSFGDV
11 BPSL2096 (101–120) KLNHYSFGDVKGELIDQLGV
12 BPSL2096 (111–130) KGELIDQLGVRDKEAGVALR
13 BPSL2096 (121–140) RDKEAGVALRATFIVDPDNT
14 BPSL2096 (131–150) ATFIVDPDNTIQHVSVNNLN
15 BPSL2096 (141–160) IQHVSVNNLNVGRSPEEILR
16 BPSL2096 (151–170) VGRSPEEILRILDGLQTDEL
17 BPSL2096 (161–182) ILDGLQTDELCPCNRAIGGATL
Table II. Relative binding affinity of AhpC peptides to HLA-DR and -DQ molecules
Results are derived from the relative binding ratio obtained by dividing the IC50 of each peptide by that of a reference peptide that binds strongly to
the HLA molecule tested. Black-shaded squares indicate high-affinity binding. Diagonally hatched squares indicate moderate binding affinity.
Unshaded squares indicate that no binding was detectable. Each peptide–MHC combination was evaluated in two independent experiments. Numerical
values for these binding assays are given in Supplemental Table I.
ND, not done.
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For intracellular cytokine staining with flow cytometry, PBMCs were
cultured in the presence of AhpC protein (0.4 mg/well) or media only for
18 h. Brefeldin A (eBioscience) was added at 10 mg/ml. After 4 h of
additional incubation, cells were stained for intracellular APC–IFN-g,
and cell surface markers (PerCP-antiCD3, FITC-antiCD4, and APC-H7-
antiCD8; BD Biosciences). Samples were analyzed using a MACSQuant
Analyzer 10 (Miltenyi Biotec) with Flowjo software.
Results
AhpC sequence contains strong HLA-DR and -DQ binding
epitopes
In view of the fact that the Salmonella typhi hydroperoxide re-
ductase is immunogenic and protective in experimental Salmo-
nellosis (24) and that the B. pseudomallei homolog is seroreactive
in clinical melioidosis (11), we set out to investigate the candidacy
of AhpC (BPSL 2096) as a T cell Ag. A synthetic peptide panel of
20 mers overlapping by 10 aa was generated, covering the full
coding sequence (Table I) and binding affinities determined for the
HLA-DR alleles, HLA-DR1, -DR3, -DR4, -DR7, -DR9, -DR11,
-DR13, -DR1501, and -DR1502 and the HLA-DQ alleles DQ6
(DQB1*0602) and DQ8 (DQB1*0302) (Table II, Supplemental
Table I). Of the 17 peptides in the panel, all were able to bind
some of the HLA alleles tested. One of the peptides, p6 (51–70), is
noteworthy in that it binds virtually all the HLA-DR and DQ
alleles tested at moderate to high affinity (Table III, Supplemental
Table I).
Immunization of HLA-DR and -DQ transgenic mice highlights
HLA class II–determined immunodominant epitopes of AhpC
Binding studies of AhpC peptides to HLA-DR and -DQ hetero-
dimers suggested a potentially complex pattern of peptide pre-
sentation to T cells. We immunized a panel of HLA-DR and -DQ
transgenic mice with recombinant AhpC protein and determined
the immunodominant T cell epitopes by IFN-g ELISPOT assay in
an in vitro recall response of lymph node T cells to the AhpC
peptide panel (Fig. 1). Patterns of response determined by the
different HLA heterodimers were distinctive: HLA-DR1 trans-
genics respond to epitopes in peptides 1, 3, 6, 7, 8, 11, 12, and 16;
HLA-DR4 transgenics respond to epitopes in peptides 6 and 14.
Of responses in the HLA-DQ transgenic lines, HLA-DQ6 mice
showed a response that was large and entirely focused on p6,
whereas HLA-DQ8 transgenics recognized p6 and p3. Thus p6 is
identified as a promiscuous and immunodominant T cell epitope
of AhpC, capable of stimulating a T cell response that encom-
passes presentation by diverse alleles of both HLA-DR and -DQ.
A peptide-specific, Ag-dependent lymphocyte IFN-g response is
likely to be made by CD4 T cells. In defining CD4 versus CD8
responses, a starting point is that, in an HLA class II transgenic
Table III. Relative binding affinity of wild-type peptide 6 and the altered variant of peptide 6 to HLA-DR heterodimers
Results depict the relative binding ratio obtained by dividing the IC50 of each peptide by that of a reference peptide that binds strongly to the HLA
molecule tested. Black-shaded squares indicate high-affinity binding. Diagonally hatched squares indicate moderate binding affinity. Unshaded
squares indicate that no binding was detectable. Each peptide–MHC combination was evaluated in two independent experiments. Numerical values
for these binding assays are given in Supplemental Table I.
BPSL2096 (51–70) p6, (KDFTFVCPTEIVEFAKLAKQ); BPSL2096 variant of p6, (KDFTFVCPTEIVEFAKQFEE).
FIGURE 1. Immunization of HLA-DR and -DQ transgenic mice highlights HLA class II determined immunodominant epitopes of AhpC. Mice
transgenic for HLA-DR1, n = 12, (A); HLA-DR4, n = 5 (B); HLA-DQ6 (DQB1*0602), n = 12 (C); and HLA-DQ8 (DQB1*0302), n = 12 (D) were primed
with 25 mg rAhpC, and draining lymph node cells were assayed with IFN-g ELISPOT in response to the indicated peptide at day 10. Data are plotted as
SFCs per 106 cells for individual mice. Responses to peptide were defined as positive if SFC . mean + 2 SD of the response in the absence of any Ag
(shown as horizontal dotted line).
The Journal of Immunology 4817
 at U
niv of St A
ndrew
s/Lib/Fife on M
ay 28, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
FIGURE 2. High-frequency T cell immune response in exposed seropositive human donors from Khon Kaen, Thailand. (A) T cell responses to heat-
killed B. pseudomallei (HK Bps) in seropositive blood donors from the Khon Kaen region (n = 33). Statistical significance was (Figure legend continues)
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mouse—knocked out for murine class II and thus with a single,
human class II molecule with which to restrict CD4 repertoire—
any IFN-g ELISPOT responses found to be Ag dependent would
be most likely to be made by CD4 T cells; the case would seem
strong considering that the peptide panel comprises 20 mers, which
would be poorly accommodated in a class I peptide-binding groove.
However, we found that a response to p6 (but not to staphylococcal
enterotoxin B superantigen) was retained in HLA class II-negative,
H2Ab-knockout mice, most compatible with the notion of presen-
tation through murine class I to CD8 cells and arguing that the
response to p6 peptide in mouse comprises both a CD4 and CD8
component (see Supplemental Fig. 1).
High-frequency T cell immune response to AhpC in exposed
seropositive human donors from Khon Kaen, Thailand
T cell ELISPOT responses to the AhpC peptide panel were ana-
lyzed in 33 B. pseudomallei–seropositive blood donors from the
B. pseudomallei–endemic region of Khon Kaen in Thailand. All
showed a positive T cell response to heat-killed B. pseudomallei
(Fig. 2A). PBMCs from the donors were then analyzed with IFN-g
ELISPOT in response to each individual, overlapping AhpC
BSPL2096 peptide. A representative donor response is shown in
Fig. 2B; eight peptides induced high-frequency T cell responses in
this donor, including p6. When responses from the full cohort of
33 seropositive donors is collated (Fig. 2C), it can be seen that at
least some of the individuals in the cohort can respond to each of
the peptides in the panel, sometimes at high frequencies of .700
SFC/106. Given the binding data showing that many of these
epitopes could be presented simultaneously by several HLA-DR
and -DQ heterodimers in each individual, these large responses
might not be surprising. The heat map representation of this
dataset (Fig. 2D) shows that the sequence encompasses hotspots of
common T cell recognition. Within this cohort, as would be an-
ticipated in this geographical region, the most common alleles are
DRB1*1202 (14 copies), DRB1*1501 (8 copies), and DRB1*0901
(8 copies). Of the 14 DRB1*1202+ donors, eight donors show
a strong response to p10, making it possible that this heterodimer
may present p10. Of the eight individuals who are DRB1*1501+,
all show a strong response to p13.
Survivors of acute melioidosis in Ubon Ratchathani have
higher T cell responses to AhpC
We then turned from analysis of T cell epitopes in healthy sero-
positive donors to analysis of T cell responses as a correlate of
disease outcome in acute melioidosis patients. Higher responses to
AhpC were seen in patients with acute melioidosis who survived
the illness (arithmetic mean response, 113 SFCs per 106 PBMCs)
compared with patients who died (arithmetic mean response, 8
SFCs per 106 PBMCs; p = 0.012; Fig. 3A). This relationship was
not seen for responses to the T cell epitope pool or an irrelevant
Ag (r47 from scrub typhus). The T cell IFN-g production in re-
sponse to AhpC protein was shown to be predominantly CD4
(Supplemental Fig. 2A, 2B) and HLA class II restricted by Ab
blocking studies (Supplemental Fig. 2C). Patients who recovered
from melioidosis also showed strong T cell responses to AhpC
12 wk later (arithmetic mean response, 103 SFCs per 106 PBMCs),
significantly higher than seronegative control subjects in the same
region (arithmetic mean response, 30 SFCs per 106 PBMCs; p =
0.0221; Fig. 3B). Interestingly, 8 of the 21 seronegative donors
show a specific response to AhpC exceeding 20 SFCs per 106
PBMCs. We interpret this to mean that, in this Burkholderia-endemic
region, there are likely to be previously exposed individuals in whom
determined using a Mann–Whitney U test. Median values with interquartile range for each group are marked. (B) T cell responses to the AhpC BPSL2096
peptide panel in a representative seropositive donor. Two SD above the mean of the media only control is shown as a horizontal dotted line. (C) Collated
peptide T cell responses in the donor panel (n = 33). Mean values for responses to each peptide are marked as a horizontal line. Responses were defined as
positive if SFCs . mean + 2 SD of the media-only control. (D) Heat map of percentile-ranked responses to each peptide in the donor panel and HLA
genotype (n = 33). All responses for a given donor are expressed as a percentage of the biggest response measured for that donor. Higher responses are
shown in red, and lower responses are shown in white. *p , 0.0001.
FIGURE 3. High T cell responses to AhpC protein are associated with survival in patients with acute melioidosis in Ubon Ratchathani. (A) Responses
measured with 18 h ex vivo IFN-g ELISPOT assay in PBMCs from patients with culture-confirmed melioidosis are shown for patients who survived (n =
30) versus those who died (n = 11). Responses were measured to 20 mg/ml AhpC protein, 1 mg/ml T cell epitope pool (“T-cell epi”) and 2 mg/ml of a scrub
typhus Ag r47. (B) Recovered melioidosis patients have strong T cell responses to AhpC. Responses to 20 mg/ml AhpC protein measured with 18 h ex vivo
IFN-g ELISPOT assay in PBMCs are shown for patients 12 wk after culture-confirmed melioidosis (n = 30) compared with seronegative control subjects at
the same hospital (n = 21). Error bars represent geometric means with 95% confidence intervals, and statistical significance was determined using the
Mann–Whitney U test.
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FIGURE 4. AhpC p6 epitope is partially deleted in a Cambodian clinical isolate, SR-039. Comparative analysis of AphC coding sequence reveals that
AhpC is almost invariant. Alignment of the amino acid sequences for AhpC from K96243 (top) and SR-039 (bottom) is shown. Three variants of the AhpC
alkyl hydroperoxide reductase protein were detected in three separate isolates; these included amino acid substitutions (A) Pro18Ala and (C) Lys123Gln and
(B) a deletion of a tripeptide at positions 67–69 (Leu-Aln-Lys)—the p6 epitope region of the AhpC protein is indicated by the box in (B).
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specific Ab has waned faster than T cell memory has. We know
that there can be divergence between exposure and seropostivity;
in a larger Ubon cohort, only 74% of individuals who survive
culture-confirmed melioidosis have IHA titers greater than 40, 12
weeks later (S. Dunachie, unpublished observations). An addi-
tional possibility is that there are epitopes within AhpC that are
conserved between B. pseudomallei and other bacterial species.
AhpC p6 epitope is partially deleted in a Cambodian clinical
isolate, SR-039
Since publication of the initial B. pseudomallei reference genome
in 2004 (25), investigators in Asia, Africa, Australia, South
America, and the Pacific have contributed clinical isolates and
data for the sequencing and curation of .200 B. pseudomallei
isolate genomes (http://www.sanger.ac.uk/resources/downloads/
bacteria/burkholderia-pseudomallei.html#t_2). Comparative analy-
sis of the AphC coding sequence revealed that AhpC is almost
invariant. Three variants of the AhpC alkyl hydroperoxide
reductase protein were detected in three separate isolates; these
included deletion of a tripeptide at positions 67 to 69 (Leu-Aln-
Lys; Fig. 4B) and amino acid substitutions Pro18Ala and
Lys123Gln (Fig. 4A, 4C). In the case of the deletion, it results in
a deletion within the p6 epitope. The strain to which this belongs
was isolated in Siem Reap, Cambodia (accession number of se-
quence data ERS090378) from a pediatric case with a parotid
abscess. However, the deletion was not seen in other isolates from
the same region (M. Holden, unpublished data). Data from
Cambodia indicates that B. pseudomallei is present in ∼30% of
rice paddies in the Siem Reap region (26).
Altered variant of peptide 6 can bind HLA class II
heterodimers, but shows little or no T cell recognition
We synthesized the wild-type and altered variant peptide of p6
(i.e., the peptide that omits LAK and has the sequence
KDFTFVCPTEIVEFAKQFEE) and measured their ability to bind
HLA class II heterodimers. For all but one of the HLA alleles
tested, we found that the variant peptide showed similar or lower
affinity binding than wild-type p6 (Table III, Supplemental Table I),
suggesting that this difference might influence immunity.
To test this suggestion, HLA transgenic mice were primed with
p6 or altered variant p6. The response of draining lymph node cells
to a titration of each peptide was then measured with INF-g
ELISPOT (Fig. 5). Across four HLA-DR and one HLA-DQ allele
tested, DLN cells generated in response to p6 were unable to re-
spond to the altered variant peptide (Fig. 5A–E). Furthermore,
there was no secretion of the cytokines IL-4, IL-5, and IL-10 (data
not shown). When mice were primed with the altered variant
peptide, no T cell recognition was elicited in the HLA back-
grounds tested, with the exception of a small response to both
peptides after priming of HLA-DR4 mice with the altered variant
peptide (Fig. 5F–I). Again, there was no secretion of the cytokines
IL-4, IL-5, and IL-10 (data not shown).
Discussion
There is a significant level of concern about a potential “time
bomb” in Asia and elsewhere, because of the convergence of an
increasing prevalence of diabetes (27) (the key risk-factor for
melioidosis) and widespread exposure in the region to environ-
mental B. pseudomallei (the causative agent for melioidosis). As
such, there is a degree of overlap between the imperatives driven
by public health in this region and by biodefense initiatives in the
United States and elsewhere to identify plausible candidates for
vaccine programs (28). In this work, we have studied AhpC as one
such candidate identified as a serodominant Ag in an earlier study
of B. pseudomallei immunogens targeted by the immune response
of patients (11). Furthermore, it has long been appreciated that
homologs of AhpC are highly immunogenic and protective in
other bacterial infections (24, 28). The relationship between AhpC
upregulation as part of the OxyR regulon, reducing the antibac-
terial effects of host-produced hydrogen peroxide and the induc-
tion of host adaptive immunity, was first demonstrated in Salmonella
typhimurium infection (24). In this setting, macrophage ex-
pression of AhpC is upregulated, but the price paid for this
upregulation is the induction of a strong CD4 T cell and Ab re-
sponse. Similarly, AhpC is highly serodominant in immunopro-
teomic analysis of the Bacillus anthracis secretome, screened with
sera from infected animals (29).
The annotated dataset of the B. pseudomallei transcriptome
reported by Tan and colleagues shows BPSL2096 to be upregu-
lated by oxidative stress or anaerobic conditions, as would be
expected, but downregulated in the context of chronic lung in-
fection (30). This report highlights the trade-off for an intracel-
lular bacterial pathogen, needing to evade innate oxidative stress
by upregulation of peroxidases, yet needing to keep expression
low to evade recognition by adaptive immunity. A key message
from the current study was the extent to which, whether assessed
in Thai seropositive human donors or in the more reductionist
setting of HLA transgenic mice, T cell responses are high fre-
quency, encompass a large number of epitopes across the protein
sequence, and have the ability to bind strongly to diverse HLA
heterodimers of different isotypes. There is evidence supporting
a role of mammalian peroxiredoxins in danger-associated mo-
lecular patterns activation: secreted peroxiredoxin family pro-
teins upregulated in the brain after stroke act as inducers of
IL-23 from infiltrating macrophages through TLR2 and TLR4
(31). That related family members can act as danger-associated
molecular patterns raises the interesting possibility that, like
bacterial flagellin Ags, the AhpC family members may con-
ceivably achieve strong immunogenicity through stimulation of
both adaptive immunity and TLRs, thus being functionally self-
adjuvanted.
A noteworthy aspect of the findings in our study was the strong
response around the p6 region of AhpC and the fact that immu-
nogenicity of this region is lost in one of the archived Cambodian
isolates. Furthermore, the p5/p6 region of immunogenicity overlies
the active site of the hydroperoxide reductase enzymatic active site
(32). Could this support a ‘Red Queen’ hypothesis (33) such that
T cell immunity has targeted a region for which the price of
mutation is disadvantageous to bacterial function? It would be
difficult to make a strong case for host immunity–driven selection
pressure forcing variation in the p6 region of the sequence;
human-to-human transmission of B. pseudomallei is described
only rarely because it is not an obligate human pathogen and, as
shown in this study and in our earlier studies, there is an abun-
dance of T cell epitopes targeted by the immune response. On the
other hand, recent data suggest the potential for significant lon-
gitudinal sequence variation in vivo, whether driven by antimi-
crobial therapy or host immunity (34, 35). We considered the
possibility that the Cambodian p6 variant sequence may be an
altered peptide ligand—that is, with the ability to signal a deviated
rather than a null response phenotype. However, we found no
evidence to suggest that any of the cytokine responses for which
we screened could be elicited in response to this sequence. The
fact that responses to the variant sequence seem to be absent, but
with the exception of a clear T cell response observed in the
context of presentation by HLA-DR4, emphasizes the point that
the immune repertoire to bacterial Ags, as to all Ags, can be ex-
quisitely sensitive to host immunogenetic variation.
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FIGURE 5. Responses of T cells from HLA class II
transgenic mice to p6 or altered variant p6. (A) HLA trans-
genic mice (n = 3 per group) expressing the alleles (A) HLA-
DR1, (B) -DR4, (C) -DQ8 (DQB1*0302), (D) -DR1502, (E)
and -DR1501 were primed with 25 mg p6 peptide in adjuvant
and draining lymph node cells assayed in triplicate by IFN-g
ELISPOT in response to the indicated peptide at day 10. They
were assayed for responses to p6 (open circle) or altered
variant p6 (open triangle). HLA transgenic mice (n = 3 per
group) expressing the alleles (F) HLA-DR1, (G) -DR4,
(H) -DQ8 (DQB1*0302), (I) -DR1502, and (J) -DR1501
were primed with 25 mg of altered variant p6 peptide in
adjuvant, and draining lymph node cells were assayed in
triplicate with IFN-g ELISPOT in response to the indicated
peptide at day 10. They were assayed for responses to p6
(open circle) or altered variant p6 (open triangle).
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An enduring conundrum in studies of B. pseudomallei immunity
has been the simple matter of focus on the key determinants of
host protection. The fact that immune dysregulation associated
with diabetes or alcohol misuse is a significant risk factor for
melioidosis—yet more explicit disruption of CD4 immunity such
as HIV infection appears less important—has supported a notion
that host defense may be largely innate (36). This study identified
eight melioidosis patients coinfected with HIV and found no ex-
plicit change in disease severity or outcome, although this is likely
too small a dataset to draw firm conclusions (36). On the other
hand, murine infection studies emphasize the importance of
classical, CD4 IFN-g bacterial immunity (8). The present study
offers two important additions to this discussion. First, human
seropositive donors who are healthy and thus presumably keeping
at bay any progression to clinical melioidosis, despite living in an
endemic region, show high frequency cumulative T cell responses
to AhpC. Second, we found that among patients with acute
melioidosis, survival was associated with a strong class II–
restricted T cell response to AhpC, a highly immunodominant
protein Ag, mapped both in the human and mouse studies. These
pieces of evidence are in line with the expectation that T cell
control of B. pseudomallei infection is indeed probably not dis-
similar to the central role of T cell control in other intracellular
bacterial infections such as Salmonella and tuberculosis (37, 38).
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Supplementary Table I. Relative binding affinity of AhpC peptides to HLA-DR 
and -DQ molecules. 
BPSL2096 
sequences 
DR1 DR3 DR4 DR7 DR9 DR11 DR13 DR1501 DR1502 DQ6 
602 
DQ8  
302 
P1 [1-20]  5 >195 1 0.8 10 3 94 12 1 562 3 2 
P2 [11-30] 15 >195 114 >358 97 217 >135 >184 >5 020 100 17 
P3 [21-40]  >2 697 >195 >140 126 110 >247 >135 >184 >5 020 >222 1 
P4 [31-50]  34 >195 65 64 22 50 >135 1 70 84 >625 
P5 [41-60] 34 >195 >140 3 4 ND >135 1 5 29 >625 
P7 [61-80]  11 >195 86 120 103 1 >135 69 95 11 16 
P8 [71-90]  17 >195 93 230 152 141 >135 >184 >5 020 179 19 
P9 [81-100]  54 >195 >140 320 540 1 7 >184 3 742 >222 >625 
P10 [91-110]  >2 697 >195 >140 360 548 115 >135 >184 3 000 >222 32 
P11 [101-120]  24 167 7 0.7 23 >247 >135 148 563 24 33 
P12 [111-130]  66 >195 52 19 107 82 >135 >184 2 175 105 7 
P13 [121-140]  2 24 10 8 355 >247 >135 23 1 151 158 2 
P14 [131-150] 1 000 3 >140 2 204 100 ND >184 300 >222 19 
P15 [141-160]  >2 697 >195 >140 64 171 158 >135 >184 >5 020 >222 >625 
P16 [151-170]  18 >195 20 >358 447 20 >135 37 2 000 >222 16 
P17 [161-182]  1 000 >195 >140 179 371 144 >135 14 1 035 >222 625 
 
P6 [51 – 70] 9 >119 9 0.3 18 43 ND 7 222 80 26 
 
Variant P6 50 >119 20 1 21 201 ND 176 >3333 >143 1 
 (KDFTFVCPTEIVEFAKQFEE) 
______________________________________________________________________________________________________ 
*Results are expressed as a relative binding ratio obtained by dividing the IC50 of each peptide by 
that of a reference peptide that binds strongly to the HLA molecule tested. Lower numbers 
correspond to a higher binding affinity. Numbers in red (ratio of 20 or less) = high affinity binding; 
numbers in green (ratio 20-100) = moderate binding affinity. Each peptide - MHC combination 
was evaluated in 2 independent experiments. ND, not done. 
 
Supplementary Figure 1 
Supplementary Figure 1. Response of H2Aβ-/- mice to the AhpC peptide 
panel. Three male mice were primed in one hind footpad with 25µg AhpC/
Titermax and DLN cells assayed at d10 for IFNγ ELIspot responses to 
individual peptides, to whole recombinant AhpC protein or to SEB (as positive 
control for class II-presented CD4 responses). A dotted line indicates mean 
medium control + 2SD. A positive peptide response is indicated by an asterisk. 
Supplementary Figure 2 
Supplementary Figure 2. CD4 and CD8 characterization of melioidosis patient 
responses to AhpC by intracellular cytokine staining (ICCS) and ELIspot. PBMC 
from 8 donors were cultured in the presence of AhpC protein (0.4µg/well) or media 
only for 18h. (A) Percent of antigen-specific IFNγ secreting cells, back-gated for CD4 
and CD8. The median % IFNγ secreting CD4 cells after AhpC stimulation for 18 hours 
was 0.11%, compared to 0.052 % for CD8 cells (n=8 subjects from Melioid Cohort 
Week 12). t-test Wilcoxon, *indicates P=0.0078. (B) Ratio of IFNγ secreting cells 
(stimulated/unstimulated) for cells back-gated on CD4 and CD8. The ratio of IFNγ 
secreting CD4 cells from AhpC stimulated to unstimulated PBMC for 18 hours was 2.9 
compared while the ratio from CD8 was 1.5 (n=8 subjects from Melioid Cohort Week 
12). t-test Wilcoxon, *indicates P=0.0078. (C) ELIspot responses to AhpC were 
measured in the presence or absence of mAbs against HLA class II (L243 and SPVL3) 
and HLA class I (W6/32). *indicates P=0.0313; ns, not significant. Data analysis by 
Wilcoxon. 
Antigen:             AhpC             AhpC              AhpC 
Antibody:               -            anti-class II      anti-class I 	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